Although the authors suggested that CART cocktail immunotherapy (CD133 CART and CART-EGFR) may be feasible for the treatment of CCA and other solid malignancies, resolving limitations that are associated with toxicities would need further investigation (Table 2) [144]. The gene discussed is EGFR; the disease is cholangiocarcinoma.